Jazz, Hikma settle Xyrem patent litigation

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) granted Hikma Pharmaceuticals plc (LSE:HIK) rights to market an authorized generic version of narcolepsy drug Xyrem sodium oxybate starting on Jan. 1, 2023. The agreement settles patent litigation between Jazz and Roxane Laboratories Inc., which Hikma acquired in 2015.

Jazz climbed $13.23 to $153.88 on Thursday. It announced the news after market hours on Wednesday...